1-Cyclopropyl-2-methylpropan-2-amine hydrochloride | 1439896-40-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-Cyclopropyl-2-methylpropan-2-amine hydrochloride
• 英文别名: 1-cyclopropyl-2-methylpropan-2-amine;hydrochloride
• CAS: 1439896-40-8
• 化学式: C7H16ClN
• 分子量: 149.66
• InChiKey: PREVHQADKKIFAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.95
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• 6-aminopyridin-3-yl pyrazoles as modulators of RORgT
  申请人：Janssen Pharmaceutica NV

  公开号：US10975057B2

  公开（公告）日：2021-04-13

  The present invention comprises compounds of Formula I. wherein: R1, Q, R3, R4, R5, R6, A1, and A2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

  本发明包括式 I 的化合物。 其中 R1、Q、R3、R4、R5、R6、A1 和 A2 的定义见说明书。 本发明还包括一种治疗或改善 ROR-γ-t 介导的综合征、紊乱或疾病的方法，其中综合征、紊乱或疾病选自由类风湿性关节炎、银屑病关节炎和银屑病组成的组。本发明还包括一种通过施用治疗有效量的至少一种式 I 化合物来调节哺乳动物体内 RORγt 活性的方法。
• 6-AMINOPYRIDIN-3-YL PYRAZOLES AS MODULATORS OF RORYT
  申请人：Janssen Pharmaceutica NV

  公开号：EP3806958A1

  公开（公告）日：2021-04-21
• [EN] 6-AMINOPYRIDIN-3-YL PYRAZOLES AS MODULATORS OF RORYT<br/>[FR] 6-AMINOPYRIDIN-3-YL PYRAZOLES EN TANT QUE MODULATEURS DE RORYT
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019244001A1

  公开（公告）日：2019-12-26

  The present invention comprises compounds of Formula I. Formula I wherein: R1, Q, R3, R4, R5, R6, A1, and A2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-ϒ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORϒt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.